LAP3 Antibody

What is LAP3 and why is it an important research target?

LAP3 (Leucine Aminopeptidase 3) is a cytosolic metallopeptidase that catalyzes the removal of unsubstituted N-terminal hydrophobic amino acids from various peptides . It plays significant roles in protein degradation and peptide metabolism. LAP3 has gained importance as a research target due to its involvement in several critical cellular processes including glutathione metabolism, cell redox status regulation, and most notably, its emerging role in cancer development . LAP3 has been associated with tumor cell proliferation, invasion, and angiogenesis in multiple cancer types, including breast cancer, hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma . Its upregulation in these malignancies makes it both a potential biomarker and therapeutic target, necessitating specific antibodies for accurate detection and characterization.

What applications are LAP3 antibodies most commonly used for in research settings?

LAP3 antibodies are versatile research tools validated for multiple applications in academic research contexts. The most common applications include:

• Immunohistochemistry-Paraffin (IHC-P): For detecting LAP3 expression in fixed tissue samples, particularly useful for studying expression patterns in tumor tissues compared to normal tissues .

• Western Blotting (WB): For quantitative assessment of LAP3 protein levels in cell and tissue lysates, essential for protein expression studies .

• Flow Cytometry (Intracellular): For analyzing LAP3 expression at the single-cell level, allowing correlation with other cellular markers .

• ELISA: For quantitative measurement of LAP3 in biological fluids and cell lysates .

When selecting antibodies, researchers should consider validation data showing specificity against LAP3 knockout cell lines, which ensures antibody specificity and reduces false-positive results .

What are the recommended validation procedures for LAP3 antibodies before experimental use?

Thorough validation of LAP3 antibodies is critical for generating reliable research data. Recommended validation procedures include:

• Specificity testing: Compare reactivity in wild-type versus LAP3 knockout cell lines (such as A549 cells) .

• Multiple application testing: Confirm antibody performance in at least two different applications (e.g., WB and IHC).

• Positive control selection: Use tissues/cells known to express LAP3 (HCC cell lines BEL-7404, HuH7, HepG2, and MHCC-97H show high LAP3 expression) .

• Negative control selection: Use normal hepatocyte cell line LO2, which shows lower LAP3 expression compared to HCC cell lines .

• Cross-reactivity assessment: Test against related aminopeptidase family members to ensure specificity.

These validation steps should be documented and included in research publications to strengthen experimental findings.

What factors affect LAP3 antibody performance in experimental settings?

Several factors can significantly impact LAP3 antibody performance:

• Fixation methods: For IHC applications, phosphate-buffered neutral formalin fixation and 5-μm-thick paraffin sections have been successfully used for LAP3 detection .

• Blocking conditions: 10% BSA blocking has shown effective results in reducing non-specific binding .

• Antibody concentration: The optimal working concentration (typically 0.05 mg/ml for some commercial antibodies) should be determined for each application .

• Incubation conditions: Overnight incubation at 4°C in a moist chamber for primary antibody application has yielded reliable results .

• Detection systems: Secondary antibodies labeled with HRP with one-hour room temperature incubation followed by diaminobenzidine treatment have proven effective .

Optimizing these parameters is essential for achieving consistent and reproducible results with LAP3 antibodies.

How can LAP3 antibodies be used to investigate the role of LAP3 in cancer cell proliferation and cell cycle regulation?

LAP3 has been implicated in cell cycle progression, particularly at the G1/S checkpoint. To investigate this role:

• Combined immunoblotting approach: Use LAP3 antibodies in conjunction with cell cycle markers including PCNA, cyclin A, CDK2, and CDK6 to establish correlation between LAP3 expression and cell cycle progression .

• LAP3 modulation experiments: Compare cell cycle profiles before and after LAP3 knockdown or overexpression using:

  • Transfection with LAP3 shRNA (target sequence: 5'-GCCCATTAATATTATAGGT-3')

  • Transfection with LAP3 overexpression vector (pcDNA3.1-LAP3)

• Flow cytometry protocol:

  • Collect cells 48 hours post-transfection

  • Perform cell cycle analysis using propidium iodide staining

  • Quantify G0/G1, S, and G2/M phase distribution

  • Correlate with LAP3 expression levels determined by western blot

This approach has revealed that LAP3 overexpression increases the percentage of cells in S phase while reducing G0/G1 phase populations, supporting LAP3's role in promoting G1/S transition in HCC cells .

What methodologies are effective for studying LAP3's involvement in IFN-γ-induced arginine depletion and malignant transformation?

The relationship between LAP3, IFN-γ signaling, and arginine metabolism requires sophisticated experimental approaches:

• Targeted metabolomics analysis: To measure arginine levels and related metabolites in response to IFN-γ treatment and LAP3 modulation .

• Signal pathway analysis: Investigate how LAP3 expression is regulated by IFN-γ through:

  • P38 inhibition using SB203580

  • ERK inhibition using PD98059

  • Western blot analysis of phosphorylated forms of these MAPKs

• Gene expression analysis: Study the effect of LAP3 on argininosuccinate synthetase (ASS1) expression through:

  • LAP3 knockdown and overexpression experiments

  • RT-qPCR and western blot analysis of ASS1 levels

  • ELISA for protein quantification

• Functional rescue experiments: Supplementing arginine to determine if it can reverse the malignant phenotypes induced by LAP3 overexpression .

This methodological framework has revealed that LAP3, regulated by p38 and ERK MAPKs, contributes to IFN-γ-induced arginine depletion by interfering with ASS1 expression, subsequently promoting malignant transformation .

How can researchers effectively use LAP3 antibodies to investigate the LAP3-HDAC2 axis in cancer development?

The LAP3-HDAC2 regulatory axis represents an important mechanism in cancer progression. To investigate this relationship:

• Co-expression analysis protocol:

  • Perform dual immunostaining for LAP3 and HDAC2 in tissue samples

  • Quantify correlation coefficients between expression patterns

  • Compare expression in normal versus tumor tissues

• Mechanistic studies:

  • Transfect cells with LAP3 expression vectors or shRNA constructs

  • Measure HDAC2 expression by western blot and qPCR

  • Use HDAC inhibitor valproate (VPA) as a control

  • Assess downstream effects on cell cycle proteins (cyclin A1 and D1)

• Chromatin immunoprecipitation (ChIP):

  • Use LAP3 antibodies to determine if LAP3 directly binds to the HDAC2 promoter

  • Alternatively, investigate indirect regulation mechanisms

• Clinical correlation analysis:

  • Measure LAP3 and HDAC2 expression in patient samples using ELISA

  • Correlate with clinical parameters and survival outcomes

  • Compare expression patterns between healthy individuals and cancer patients

This approach has established that LAP3 contributes to malignant transformation partly through upregulation of HDAC2 expression, which subsequently promotes cell cycle proteins cyclin A1 and D1 .

What approaches should be used when investigating LAP3's role in chemotherapy resistance?

LAP3 has been implicated in drug resistance mechanisms, particularly to cisplatin. To investigate this aspect:

• Cell viability assays:

  • Treat LAP3-modulated cells (overexpression or knockdown) with increasing concentrations of cisplatin

  • Determine IC50 values using MTT or similar viability assays

  • Calculate resistance index by comparing IC50 values between LAP3-modified and control cells

• Apoptosis analysis protocol:

  • Treat cells with cisplatin for 24-48 hours

  • Perform Annexin V/PI staining for flow cytometry

  • Alternatively, measure caspase-3/7 activation

  • Compare apoptotic rates between LAP3-high and LAP3-low populations

• Combination therapy testing:

  • Use LAP3 inhibitor bestatin in combination with cisplatin

  • Determine synergistic effects using Chou-Talalay method

  • Analyze downstream signaling pathways affected by the combination

• In vivo xenograft studies:

  • Establish tumor xenografts with LAP3-high and LAP3-low cells

  • Treat with cisplatin according to established protocols

  • Monitor tumor growth, analyze tumor tissues for apoptotic markers

  • Correlate treatment response with LAP3 expression

These methodologies have demonstrated that knockdown of LAP3 enhances the sensitivity of HCC cells to cisplatin, suggesting LAP3 inhibition as a potential strategy to overcome chemoresistance .

What are the optimal conditions for LAP3 antibody usage in different experimental applications?

These conditions should be optimized for each specific antibody and experimental system to achieve optimal signal-to-noise ratios and reproducible results .

How can researchers distinguish between LAP3 and other closely related aminopeptidases?

Distinguishing LAP3 from other aminopeptidase family members requires careful experimental design:

• Antibody selection strategy:

  • Choose antibodies raised against unique epitopes of LAP3

  • Confirm specificity against recombinant LAP3 protein

  • Verify absence of cross-reactivity with other aminopeptidases

• Functional assays:

  • Exploit LAP3's dependence on Zn2+ ions for peptidase activity

  • Use Mn2+ to enhance LAP3's specific Cys-Gly hydrolyzing activity

  • Employ bestatin as a selective LAP3 inhibitor in validation experiments

• Gene expression analysis:

  • Design highly specific primers for LAP3 (NM_015907.2)

  • Combine with protein detection for confirmation

  • Compare expression patterns with other aminopeptidases

• Subcellular localization:

  • LAP3 is predominantly cytosolic, which can help distinguish it from membrane-bound aminopeptidases

  • Use cell fractionation followed by western blotting

  • Alternatively, use immunofluorescence with confocal microscopy

These approaches collectively ensure accurate identification and characterization of LAP3 in experimental systems.

What troubleshooting strategies are effective when LAP3 antibodies yield inconsistent results?

When encountering inconsistent results with LAP3 antibodies, consider these troubleshooting approaches:

• Antibody validation review:

  • Confirm antibody specificity using LAP3 knockout controls

  • Test multiple antibody clones targeting different epitopes

  • Validate with positive controls (HCC cell lines) and negative controls (LO2 cells)

• Sample preparation optimization:

  • For protein extraction, use RIPA lysis buffer containing 1% protease inhibitor

  • Centrifuge cell lysates at 12,000 g, 4°C for 10 minutes to obtain cell-free supernatant

  • Standardize protein quantification methods

• Technical parameter adjustment:

  • Modify antibody concentration (titration experiments)

  • Adjust incubation times and temperatures

  • Test different blocking agents to reduce background

• Signal detection enhancement:

  • For weak signals, consider amplification systems

  • For western blots, extend exposure times or use more sensitive substrates

  • For IHC, optimize antigen retrieval methods

• Multi-method confirmation:

  • Verify results using at least two different detection methods

  • Combine protein and mRNA detection approaches

  • Consider mass spectrometry validation for ambiguous results

Systematic application of these troubleshooting strategies can resolve most issues related to LAP3 antibody performance across different experimental contexts.

How should researchers interpret LAP3 expression patterns in cancer tissues compared to normal tissues?

Interpreting LAP3 expression patterns requires careful consideration of several factors:

• Expression level assessment:

  • LAP3 is significantly upregulated in multiple cancer types compared to normal tissues

  • In HCC, LAP3 shows markedly higher expression than in normal liver samples

  • In breast cancer patients, LAP3 is upregulated while ASS1 is downregulated compared to healthy controls

• Subcellular localization analysis:

  • LAP3 is predominantly localized in the cytoplasm of HCC cells

  • Changes in localization patterns may indicate altered function

• Correlation with clinical parameters:

  • High LAP3 expression correlates with lower differentiation, positive lymph node metastasis, and high Ki-67 expression in HCC, indicating poor prognosis

  • Systematically document correlations with tumor grade, stage, and patient outcomes

• Contextual interpretation considerations:

  • Compare LAP3 expression with related pathway components (ASS1, HDAC2)

  • Consider tissue-specific variations in baseline expression

  • Account for tumor heterogeneity by analyzing multiple regions

These interpretative frameworks help translate LAP3 expression data into clinically and biologically meaningful information.

What methodological approaches should be used to study the interaction between LAP3 and inflammation in disease models?

Given LAP3's involvement in inflammatory processes, particularly IFN-γ-mediated pathways, specialized approaches are needed:

• In vitro inflammation modeling:

  • Stimulate cells with bovine IFN-γ (commercially available from suppliers like Kingfisher Biotech)

  • Monitor LAP3 expression changes using western blot, qPCR, and ELISA

  • Analyze temporal expression patterns through time-course experiments

• Signaling pathway dissection:

  • Use specific inhibitors for p38 (SB203580) and ERK (PD98059) pathways

  • Determine their effects on IFN-γ-induced LAP3 expression

  • Map the signaling cascade through phosphorylation studies

• Metabolic impact assessment:

  • Employ LC-MS/MS-based targeted metabolomics to analyze arginine metabolism

  • Use isotope-labeled amino acids to track metabolic flux

  • Correlate metabolic changes with LAP3 expression levels

• Inflammatory cytokine profiling:

  • Measure multiple inflammatory markers alongside LAP3

  • Determine whether LAP3 acts upstream or downstream of key inflammatory mediators

  • Study potential feedback mechanisms

This methodology has revealed that LAP3 expression is upregulated along with other inflammatory cytokines following viral infections, including SARS-CoV-2, suggesting broader roles in inflammatory responses beyond cancer .

How can LAP3 antibodies be utilized in developing potential therapeutic strategies targeting LAP3?

LAP3 antibodies are valuable tools in developing therapeutic strategies:

• Target validation studies:

  • Confirm LAP3 overexpression in patient-derived samples using immunohistochemistry

  • Correlate expression with clinical outcomes to establish relevance

  • Demonstrate functional dependency through knockdown/knockout studies

• Mechanistic exploration for drug development:

  • Use LAP3 antibodies to monitor protein levels following treatment with candidate compounds

  • Identify interactions with key binding partners through co-immunoprecipitation

  • Study post-translational modifications that affect LAP3 function

• Therapeutic antibody development pipeline:

  • Screen for antibodies that can inhibit LAP3 enzymatic activity

  • Test antibody-drug conjugates targeting LAP3-expressing cells

  • Evaluate internalization of LAP3-antibody complexes

• Combination therapy assessment:

  • Monitor LAP3 levels during treatment with established therapies

  • Evaluate synergistic potential of LAP3 inhibition with standard treatments

  • Combine LAP3 inhibitor bestatin with conventional chemotherapeutics like cisplatin

Research has demonstrated that LAP3 inhibition enhances sensitivity to cisplatin in HCC cells, suggesting LAP3-targeted approaches could overcome chemoresistance mechanisms in cancer therapy .

What emerging technologies could enhance the specificity and sensitivity of LAP3 detection?

Several cutting-edge technologies show promise for advancing LAP3 detection:

• Proximity ligation assays (PLA):

  • Allow detection of protein-protein interactions in situ

  • Could reveal LAP3 interactions with binding partners like HDAC2

  • Provide higher specificity than conventional co-immunoprecipitation

• CRISPR-based tagging systems:

  • Enable endogenous tagging of LAP3 with fluorescent proteins

  • Allow real-time tracking of LAP3 dynamics in living cells

  • Provide validation controls for antibody specificity

• Advanced mass spectrometry:

  • Use of AQUA peptides for absolute quantification of LAP3

  • Analysis of post-translational modifications affecting function

  • Detection of LAP3-associated protein complexes

• Single-cell proteomics:

  • Measure LAP3 expression at single-cell resolution

  • Correlate with other markers to identify distinct cellular subpopulations

  • Reveal heterogeneity in LAP3 expression within tumors

These technologies can overcome current limitations in specificity, sensitivity, and contextual understanding of LAP3 biology.

What are the most promising avenues for studying LAP3's role in cellular redox regulation?

LAP3's involvement in glutathione metabolism suggests important functions in redox regulation:

• Redox proteomics approach:

  • Use selective labeling of oxidized proteins

  • Compare redox states in LAP3-modulated cells

  • Identify redox-sensitive proteins affected by LAP3

• Glutathione metabolism analysis:

  • Measure GSH/GSSG ratios in LAP3-overexpressing or depleted cells

  • Track glutathione conjugate processing using fluorescent reporters

  • Study Cys-Gly-S-conjugate dipeptidase activity of LAP3 in the presence of Mn2+

• Live-cell redox imaging:

  • Use genetically encoded redox sensors (e.g., roGFP)

  • Monitor real-time changes in cellular redox state

  • Correlate with LAP3 activity manipulations

• Oxidative stress challenge models:

  • Expose LAP3-modified cells to oxidative stressors

  • Assess survival, damage markers, and adaptive responses

  • Determine if LAP3 inhibition sensitizes cells to oxidative stress

These approaches can elucidate LAP3's contribution to redox homeostasis, potentially revealing new therapeutic opportunities in conditions with dysregulated redox balance.